Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 11;10(10):101379.
doi: 10.1016/j.jacbts.2025.101379. Online ahead of print.

Acellular Tissue Engineered Vessels as Coronary Artery Bypass Grafts

Affiliations
Free article

Acellular Tissue Engineered Vessels as Coronary Artery Bypass Grafts

Adam R Williams et al. JACC Basic Transl Sci. .
Free article

Abstract

Coronary artery bypass graft (CABG) uses the patient's internal mammary artery and saphenous vein; however, unavailable or poor quality autologous vessels limit revascularization. This study addresses the critical need for alternative CABG conduits by evaluating a small diameter acellular tissue-engineered vessel ([sdATEV], 3.5 mm) in a primate model. Adult baboons (n = 5) underwent CABG to the right coronary artery (RCA) with an sdATEV. Patency, diameter, and cardiac function were longitudinally assessed by computed tomography angiography. All sdATEVs remained patent throughout the 6-month study. Computed tomography angiography demonstrated that the distal sdATEV diameter gradually remodeled to approximate the smaller baboon RCA. Histology and spatial transcriptomics revealed that sdATEVs recellularized with host endothelial and smooth muscle cells including a quiescent neomedia layer with gene expression patterns similar to the RCA, indicating that host cell ingrowth from the bypassed coronary artery regulates sdATEV diameter. These results suggest that the sdATEV is a durable alternative CABG conduit.

Keywords: coronary artery bypass graft; coronary computed tomography angiography; regenerative medicine; spatial genomics; tissue engineering; vascular biology.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures The work described in this paper was fully funded by Humacyte Global, Inc. Drs Nash, Kirkton, Levitan, Naegeli, Prichard, and Niklason are employed by Humacyte Global, Inc and own stock or stock options in Humacyte Global, Inc. Drs Benkert and McCartney, have received consulting fees from Humacyte Global, Inc. Dr Kypson has received consulting fees from Humacyte Global, Inc.; and owns stock or stock options in Humacyte Global, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

LinkOut - more resources